{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"51.0","upperLimit":"812.0","value":"109.0"},{"groupId":"OG001","lowerLimit":"49.0","upperLimit":"71.0","value":"56.0"},{"groupId":"OG002","lowerLimit":"49.0","upperLimit":"812.0","value":"56.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"17"},{"groupId":"OG002","value":"21"}],"units":"Participants"}],"description":"TTR for PTCL was defined as the time in days from first dose date to the first date of objective disease response.","dispersionType":"Full Range","groups":[{"description":"Romidepsin 14mg/m\\^2 by intravenous (IV) infusion on Days 1, 8, 15 of each 28-day cycle.","id":"OG000","title":"Phase 1: Romidepsin 14mg/m^2"},{"description":"Romidepsin 14mg/m\\^2 by intravenous (IV) infusion on Days 1, 8, 15 of each 28-day cycle.","id":"OG001","title":"Phase 2: Romidepsin 14mg/m^2"},{"description":"Romidepsin 14mg/m\\^2 by intravenous (IV) infusion on Days 1, 8, 15 of each 28-day cycle.","id":"OG002","title":"Total: Romidepsin 14mg/m^2"}],"paramType":"MEDIAN","populationDescription":"Intent to treat population for participants with PTCL who received at least one dose of romidepsin and achieved a PR or better (CR, CRu or PR)","reportingStatus":"POSTED","timeFrame":"Median follow-up time was 100 days; up to the data cut-off of 28 July 2015","title":"Time to Response (TTR) for PTCL Participants With at Least a PR Based on the Modified 1999 IWC as Assessed by IER","type":"SECONDARY","unitOfMeasure":"days"}